A new case report was published in Volume 12 of Oncoscience on December 23, 2025, titled “Silent toxicity: A rare case of ...
The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk ...
Purple Biotech Ltd. announced a significant study revealing that their drug NT219, combined with 5-fluorouracil (5-FU), effectively inhibits colorectal cancer brain metastasis by targeting the IRS2 ...
Though SE was the most effective therapy for Bowen disease, the risk for recurrence with 5-FU and MAL-PDT was negligible.
The patient's symptoms resolved after permanently stopping 5-FU and administering lactulose and intravenous fluids, therefore supporting the ...
PURPOSE: To compare protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin (MMC) in patients with advanced pancreatic cancer in a multicenter, prospectively randomized study ...
Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical ...
HANOVER, MD, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results